---

Highlights of Deals in July 2024

1.     Mankind to acquire Bharat Serums and Vaccines (BSV) from Advent International for INR 13,600 crore (USD$1.636 Billion).

2.     Medtronic invests US$60 Million in India its 1st global IT centre outside US.

3.     Zydus inks licensing pact with Takeda to sell GERD drug.

4.     Mankind Pharma inks pact with Takeda to commercialize Vonoprazan in India.

5.     Lupin inks pact with Huons to market Ophthalmic Nanoemulsion in Mexico.

6.     Dr Reddy's inks licensing pact with Takeda to sell gastrointestinal drug.

7.     Thyrocare acquires Polo Labs Private Limited’s pathology diagnostic business.

8.     Agilent to buy contract drug manufacturer Biovectra for US$925 Million.

9.     Alcon inks US$466 Million deal for Belkin Vision's automated laser therapy for glaucoma.

10.  Nvidia, Pfizer lead $80 Million funding for Israeli medical AI tech firm CytoReason.

11.  SmartCella raises EUR 50 Million from institutional investors; enters license agreement with XyloCor Therapeutics.

12.  Genovis completes strategic investment in Sequrna, a developer of next-generation RNase inhibitors.

13.  Radiopharma-focused Pentixapharm picks up Glycotope's discovery unit for preclinical cancer antibodies.

14.  AddLife acquires BonsaiLab, a Spanish distributor in the field of cell and molecular biology.

 

Aagami Updates:

1.     Success Story: Venture Capital Arm of a large global pharma group invests in Aagami MedTech client from California.

2.     Aagami received contract extension from US based Genetic Engineering company prepared to counter the next Global threat of Autoimmune diseases.

3.     Biosimilar focused subsidiary of a Global Pharma awards contract extension to Aagami.

4.     Like every year, Aagami will attend Bio-Europe partnering conference in Stockholm, Sweden (Nov 4-6, 2024).

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses.

2.     Licensing: Several Biosimilars available for Partnering in multiple regions like Japan

3.     Seeking Acquisition /JV – Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial ongoing in AU).

4. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Sale of equity owned by an Investor who passed away (in a genetic engineering and therapeutics Co. from New York)

2.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

3.     IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

4.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
2. Seeking US$3 million: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity.
3. Seeking US$5 million: Integrated Autoimmune company leading the Next Healthcare Revolution by Uncovering the drivers of autoimmune diseases to advance therapeutic assets.

Hope you found the content useful. We welcome your feedback and queries.